Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

• Status: RECRUITING
• Trial end date: 2025-12-30

Summary

The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.

• Phase: PHASE3

Details

• Lead Sponsor: Wuhan Createrna Science and Technology Co., Ltd